Research programme: plasmin inhibitors - Omeros

Drug Profile

Research programme: plasmin inhibitors - Omeros

Alternative Names: OMS 616

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at Los Angeles
  • Developer Omeros Corporation
  • Class Proteins
  • Mechanism of Action Blood coagulation factor modulators; Plasmin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Haemorrhage

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for preclinical development in Haemorrhage in USA
  • 16 Mar 2017 Omeros Corporation has patent protection for plasmin inhibitors in USA and ex-US countries
  • 23 May 2014 Preclinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top